Blockade of Interleukin Seventeen (IL-17A) with Secukinumab in Hospitalized COVID-19 patients - the BISHOP study.

BackgroundPatients with severe COVID-19 seem to have a compromised antiviral response and hyperinflammation. Neutrophils are critical players in COVID-19 pathogenesis. IL-17A plays a major role in protection against extracellular pathogens and neutrophil attraction and activation. We hypothesized that secukinumab, an anti-IL17A monoclonal antibody, could mitigate the deleterious hyperinflammation in COVID-19. MethodsBISHOP... Show more